Global and disease-associated genetic variation in the human Fanconi anemia gene family

Human Molecular Genetics

Volumn 23, Issue 25, 2014, Pages 6815-6825

  Rogers, Kai J ^a   Fu, Wenqing ^a   Akey, Joshua M ^a   Monnat, Raymond J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; BRIP1 PROTEIN, HUMAN; DNA BINDING PROTEIN; FANCONI ANEMIA PROTEIN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; RAD51C PROTEIN, HUMAN; RNA HELICASE; TUMOR SUPPRESSOR PROTEIN; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ALGORITHM; EXOME; FANCONI ANEMIA; GENE EXPRESSION; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HIGH THROUGHPUT SEQUENCING; HUMAN; MULTIGENE FAMILY; MUTATION RATE; PATHOLOGY; RECESSIVE GENE;

ALGORITHMS; BRCA2 PROTEIN; DNA-BINDING PROTEINS; EXOME; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; GENE EXPRESSION; GENES, RECESSIVE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MULTIGENE FAMILY; MUTATION RATE; NUCLEAR PROTEINS; RNA HELICASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84986563414     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu400     Document Type: Article

References (63)

1. Fanconi, G. (1967) Familial constitutional panmyelocytopathy, Fanconi’s anemia (F.A.). Semin. Hematol., 4, 233–241.
2. Schroeder, T.M., Tilgen, D., Kruger, J. and Vogel, F. (1976) Formal genetics of Fanconi anemia. Hum. Genet., 32, 257 – 288.
3. Auerbach, A.D. (2009) Fanconi anemia and its diagnosis. Mutat. Res., 668, 4–10.
4. Neveling, K., Endt, D., Hoehn, H. and Schindler, D. (2009) Genotype–phenotype correlations in Fanconi anemia. Mutat. Res., 668, 73–91.
5. Alter, B.P. (2003) Cancer in Fanconi anemia, 1927–2001. Cancer, 97, 425–440.
6. Rosenberg, P.S., Greene, M.H. and Alter, B.P. (2003) Cancer incidence in persons with Fanconi anemia. Blood, 101, 822–826.
7. Kutler, D.I., Singh, B., Satagopan, J., Batish, S.D., Berwick, M., Giampietro, P.F., Hanenberg, H. and Auerbach, A.D. (2003) A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood, 101, 1249 – 1256.
8. Rosenberg, P.S., Alter, B.P. and Ebell, W. (2008) Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica, 93, 511–517.
9. Alter, B.P., Giri, N., Savage, S.A., Peters, J.A., Loud, J.T., Leathwood, L., Carr, A.G., Greene, M.H. and Rosenberg, P.S. (2010) Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br. J. Haematol., 150, 179–188.
10. Kee, Y. and D’Andrea, A.D. (2012) Molecular pathogenesis and clinical management of Fanconi anemia. J. Clin. Invest., 122, 3799–3806.
11. Garaycoechea, J.I. and Patel, K.J. (2013) Why does the bone marrow fail in Fanconi anemia?. Blood, 123, 26–34.
12. de Winter, J.P. and Joenje, H. (2009) The genetic and molecular basis of Fanconi anemia. Mutat. Res., 668, 11–19.
13. Consortium, T.G.P. (2012) An integrated map of genetic variation from 1,092 human genomes. Nature, 491, 56–65.
14. NHLBI Exome Sequencing Project Exome Variant Server (2014) http://evs.gs.washington.edu/EVS/ (date last accessed, 9 April 2014).
15. Fu, W., O/’Connor, T.D., Jun, G., Kang, H.M., Abecasis, G., Leal, S.M., Gabriel, S., Altshuler, D., Shendure, J., Nickerson, D.A. et al. (2013) Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature, 493, 216–220.
16. NHGRI Breast Cancer Information Core (2014) BIC: The Breast Cancer Information Core: http://research.nhgri.nih.gov/bic/ (date last accessed, 7 August 2014).
17. Howlett, N.G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., de Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G. et al. (2002) Biallelic inactivation of BRCA2 in Fanconi Anemia. Science, 297, 606–609.
18. Hirsch, B., Shimamura, A., Moreau, L., Baldinger, S., Hag-alshiekh, M., Bostrom, B., Sencer, S. and D’Andrea, A.D. (2004) Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood, 103, 2554 – 2559.
19. Offit, K., Levran, O., Mullaney, B., Mah, K., Nafa, K., Batish, S.D., Diotti, R., Schneider, H., Deffenbaugh, A., Scholl, T. et al. (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J. Natl. Cancer Inst., 95, 1548–1551.
20. Wagner, J.E., Tolar, J., Levran, O., Scholl, T., Deffenbaugh, A., Satagopan, J., Ben-Porat, L., Mah, K., Batish, S.D., Kutler, D.I. et al. (2004) Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood, 103, 3226 – 3229.
21. Myers, K., Davies, S.M., Harris, R.E., Spunt, S.L., Smolarek, T., Zimmerman, S., McMasters, R., Wagner, L., Mueller, R., Auerbach, A.D. et al. (2012) The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediat. Blood Cancer, 58, 462 – 465.
22. King, M.-C., Marks, J.H. and Mandell, J.B. and New York Breast Cancer Study Group. (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643–646.
23. O’Roak, B.J., Vives, L., Fu, W., Egertson, J.D., Stanaway, I.B., Phelps, I.G., Carvill, G., Kumar, A., Lee, C., Ankenman, K. et al. (2012) Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science, 338, 1619 – 1622.
24. Dohm, J.C., Lottaz, C., Borodina, T. and Himmelbauer, H. (2008) Substantial biases in ultra-short read data sets from high-throughput DNA sequencing. Nucleic Acids Res., 36, e105.
25. Allhoff, M., Schonhuth, A., Martin, M., Costa, I., Rahmann, S. and Marschall, T. (2013) Discovering motifs that induce sequencing errors. BMC Bioinform., 14, S1.
26. Ng, P.C. and Henikoff, S. (2001) Predicting deleterious amino acid substitutions. Genome Res., 11, 863–874.
27. Kumar, P., Henikoff, S. and Ng, P.C. (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protocols, 4, 1073 – 1081.
28. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S. and Sunyaev, S.R. (2010) A method and server for predicting damaging missense mutations. Nat. Methods, 7, 248 – 249.
29. Chun, S. and Fay, J.C. (2009) Identification of deleterious mutations within three human genomes. Genome Res., 19, 1553–1561.
30. Schwarz, J.M., Rodelsperger, C., Schuelke, M. and Seelow, D. (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods, 7, 575 – 576.
31. Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A. and Batzoglou, S. (2010) Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput. Biol., 6, e1001025.
32. Pollard, K.S., Hubisz, M.J., Rosenbloom, K.R. and Siepel, A. (2010) Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res., 20, 110–121.
33. Aartsma-Rus, A. (2012) Overview on DMD exon skipping. Methods Mol. Biol., 867, 97–116.
34. Hoffman, E.P., Bronson, A., Levin, A.A., Takeda, S.i., Yokota, T., Baudy, A.R. and Connor, E.M. (2011) Restoring dystrophin expression in Duchenne muscular dystrophy muscle: progress in exon skipping and stop codon read through. Am. J. Pathol., 179, 12 – 22.
35. Goyenvalle, A., Seto, J.T., Davies, K.E. and Chamberlain, J. (2011) Therapeutic approaches to muscular dystrophy. Hum. Mol. Genet., 20, R69–R78.
36. Schweingruber, C., Rufener, S.C., Zünd, D., Yamashita, A. and Mühlemann, O. (2013) Nonsense-mediated mRNA decay—mechanisms of substrate mRNA recognition and degradation in mammalian cells. Biochim. Biophys. Acta, 1829, 612 – 623.
37. Huang, L. and Wilkinson, M.F. (2012) Regulation of nonsense-mediated mRNA decay. Wiley Interdiscp Rev RNA, 3, 807–828.
38. Bidou, L., Allamand, V., Rousset, J.-P. and Namy, O. (2012) Sense from nonsense: therapies for premature stop codon diseases. Trends Mol. Med., 18, 679–688.
39. Keeling, K.M., Wang, D., Conard, S.E. and Bedwell, D.M. (2012) Suppression of premature termination codons as a therapeutic approach. Crit. Rev. Biochem. Mol. Biol., 47, 444–463.
40. Rosenberg, P.S., Tamary, H. and Alter, B.P. (2011) How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am. J. Med. Genet. A, 155, 1877–1883.
41. Auerbach, A.D. and Lach, F. (2013) The Fanconi Anemia Mutation Database: http://www.rockefeller.edu/fanconi/mutate/ (date last accessed, 7 August 2014).
42. Tennessen, J.A., Bigham, A.W., O’Connor, T.D., Fu, W., Kenny, E.E., Gravel, S., McGee, S., Do, R., Liu, X., Jun, G. et al. (2012) Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science, 337, 64–69.
43. Ameziane, N., Errami, A., Léveillé, F., Fontaine, C., de Vries, Y., van Spaendonk, R.M.L., de Winter, J.P., Pals, G. and Joenje, H. (2008) Genetic subtyping of Fanconi anemia by comprehensive mutation screening. Hum. Mutat., 29, 159–166.
44. Chandrasekharappa, S.C., Lach, F.P., Kimble, D.C., Kamat, A., Teer, J.K., Donovan, F.X., Flynn, E., Sen, S.K., Thongthip, S., Sanborn, E. et al. (2013) Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. Blood, 121, e138–e148.
45. Mills, R.E., Walter, K., Stewart, C., Handsaker, R.E., Chen, K., Alkan, C., Abyzov, A., Yoon, S.C., Ye, K., Cheetham, R.K. et al. (2011) Mapping copy number variation by population-scale genome sequencing. Nature, 470, 59 – 65.
46. MacArthur, D.G., Balasubramanian, S., Frankish, A., Huang, N., Morris, J., Walter, K., Jostins, L., Habegger, L., Pickrell, J.K., Montgomery, S.B. et al. (2012) A systematic survey of loss-of-function variants in human protein-coding genes. Science, 335, 823 – 828.
47. Xue, Y., Chen, Y., Ayub, Q., Huang, N., Ball, E.V., Mort, M., Phillips, A.D., Shaw, K., Stenson, P.D., Cooper, D.N. et al. (2012) Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am. J. Hum. Genet., 91, 1022 – 1032.
48. Berwick, M., Satagopan, J.M., Ben-Porat, L., Carlson, A., Mah, K., Henry, R., Diotti, R., Milton, K., Pujara, K., Landers, T. et al. (2007) Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res., 67, 9591–9596.
49. McElroy, S.P., Nomura, T., Torrie, L.S., Warbrick, E., Gartner, U., Wood, G. and McLean, W.H.I. (2013) A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol., 11, e1001593.
50. Dietz, H.C. (2010) New therapeutic approaches to Mendelian disorders. N Engl. J. Med., 363, 852–863.
51. Rogan, M.P., Stoltz, D.A. and Hornick, D.B. (2011) Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest, 139, 1480–1490.
52. Bear, C.E., Li, C., Kartner, N., Bridges, R.J., Jensen, T.J., Ramjeesingh, M. and Riordan, J.R. (1992) Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell, 68, 809–818.
53. Rowe, S.M., Miller, S. and Sorscher, E.J. (2005) Cystic fibrosis. New Engl. J. Med., 352, 1992–2001.
54. Van Goor, F., Hadida, S., Grootenhuis, P.D.J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A. et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA, 106, 18825–18830.
55. Accurso, F.J., Rowe, S.M., Clancy, J.P., Boyle, M.P., Dunitz, J.M., Durie, P.R., Sagel, S.D., Hornick, D.B., Konstan, M.W., Donaldson, S.H. et al. (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl. J. Med., 363, 1991–2003.
56. Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Dřevínek, P., Griese, M., McKone, E.F., Wainwright, C.E., Konstan, M.W. et al. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl. J. Med., 365, 1663 – 1672.
57. Jih, K.-Y. and Hwang, T.-C. (2013) Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl. Acad. Sci. USA, 110, 4404–4409.
58. Antonarakis, S.E. and Group, T.N.W. (1998) Recommendations for a nomenclature system for human gene mutations. Hum. Mutat., 11, 1–3.
59. den Dunnen, J.T. and Antonarakis, S.E. (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat., 15, 2–7.
60. Kimura, M. and Crow, J.F. (1964) The number of alleles that can be maintained in a finite population. Genetics, 49, 725–738.
61. Kuhn, R.M., Haussler, D. and Kent, W.J. (2013) The UCSC genome browser and associated tools. Brief. Bioinform., 14, 144 – 161.
62. Meyer, L.R., Zweig, A.S., Hinrichs, A.S., Karolchik, D., Kuhn, R.M., Wong, M., Sloan, C.A., Rosenbloom, K.R., Roe, G., Rhead, B. et al. (2013) The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res., 41, D64 – D69.
63. ENCODE Project Consortium. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57–74.